TY  - GEN
AU  - Turtle,Cameron J
AU  - Hanafi,Laïla-Aïcha
AU  - Berger,Carolina
AU  - Hudecek,Michael
AU  - Pender,Barbara
AU  - Robinson,Emily
AU  - Hawkins,Reed
AU  - Chaney,Colette
AU  - Cherian,Sindhu
AU  - Chen,Xueyan
AU  - Soma,Lorinda
AU  - Wood,Brent
AU  - Li,Daniel
AU  - Heimfeld,Shelly
AU  - Riddell,Stanley R
AU  - Maloney,David G
TI  - Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
SN  - 1946-6242
PY  - 2017///1211
KW  - Adult
KW  - Aged
KW  - Biomarkers, Tumor
KW  - metabolism
KW  - CD4-Positive T-Lymphocytes
KW  - immunology
KW  - CD8-Positive T-Lymphocytes
KW  - Cell Proliferation
KW  - Cyclophosphamide
KW  - pharmacology
KW  - Female
KW  - Humans
KW  - Immunotherapy
KW  - adverse effects
KW  - Lymphocyte Depletion
KW  - Lymphocyte Subsets
KW  - Lymphoma, Non-Hodgkin
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Receptors, Antigen, T-Cell
KW  - Syndrome
KW  - Transgenes
KW  - Treatment Outcome
KW  - Vidarabine
KW  - analogs & derivatives
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1126/scitranslmed.aaf8621
ER  -